GeneDx Holdings Corp at Goldman Sachs Healthcare Conference Transcript
All right. Good morning, everyone. Thanks for being here today. Dave Delahunt, life science tools and diagnostics team, and here we're joined with the team here with Katherine Stueland. And if we could get started with -- if you could just give an overview of the state of the business in Q2 and how the restructuring efforts have progressed.
So good to be here. Thank you for hosting us. So just taking a step back at what we've been able to do over the past several years with GeneDx. I'm actually entering year 3 leading the company. And as you said, year 2 last year included our merger with Sema4 and really entailed a lot of restructuring of the company. And I'm happy to say that we're really focused on 3 main goals as a management team and we really embarked on this just about a year ago.
So one is sustainably growing the company by way of revenues and really continuing to drive gross margins and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
